Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegloxenatide (PEX168) + Metformin in T2DM
NCT02477969Phase 3Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Feb 2014
- Primary completion
- Jun 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of polyethylene glycol loxenatide in type 2 diabetes mellitus (T2DM), sponsored by Hansoh Pharmaceutical Group. Status: unknown.
02
Drugs
polyethylene glycol loxenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02477969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02477969.